CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

2/24/26 12:30:00 PM ET

$COSM

Other Pharmaceuticals

Health Care

Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to Book Value

CHICAGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today highlighted the intrinsic value of its wholly owned real estate portfolio and announced that it is evaluating strategic monetization options to unlock shareholder value. Based on independent valuation reports, recent market data, and comparable transactions, management estimates the combined fair market value of the Company's Cana Laboratories ("Cana") manufacturing facility and CosmoFarm logistics center at approximately $15 million. This estimate reflects the value of the land and buildings only and excludes t

2/19/26 11:30:00 AM ET

$COSM

Other Pharmaceuticals

Health Care

Cosmos Health Continues UK Retail Expansion for C-Scrub; Now Available at Superdrug, the UK's Second-Largest Beauty and Health Retailer

CHICAGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced continued expansion of its United Kingdom (UK) retail footprint as its antimicrobial skin cleanser, C-Scrub Wash Chlorhexidine 4% ("C-Scrub"), is now available through Superdrug, the UK's second-largest beauty and health retailer. Established over 60 years ago, Superdrug is widely recognized for its leadership in health, wellness, and personal care categories and operates more than 830 stores across the UK and the Republic of Ireland, including over 200 in-store pharmacies and a growing number of healt

2/18/26 1:45:00 PM ET

$COSM

Other Pharmaceuticals

Health Care

$COSM
Leadership Updates

Live Leadership Updates

View All

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

2/24/26 12:30:00 PM ET

$COSM

Other Pharmaceuticals

Health Care

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

CHICAGO, April 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Highlights Income Statement: FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses, while bottom-line results were impacted by the absence of non-recurring gain

4/16/25 12:45:15 PM ET

$COSM

Other Pharmaceuticals

Health Care

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

CHICAGO, IL / ACCESSWIRE / December 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology at the Company's Research and Development division.Professor Trafalis currently serves as a Professor of Pharmacology and Clinical Pharmacology at the Faculty of Medicine, National and Kapodistrian University of Athens.He is a medical specialist in onc

12/26/24 1:30:00 PM ET

$COSM

Other Pharmaceuticals

Health Care

$COSM
Financials

Live finance-specific insights

View All

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025. As a result of these transactions, Mr. Siokas now beneficially owns 5,582,066 common shares in Cosmos Health. Greg S

4/30/25 12:50:09 PM ET

$COSM

Other Pharmaceuticals

Health Care

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 647,809 common shares, valued at $425,000, across six transactions between December 20, 2024, and January 17, 2025.As a result of these transactions, Mr. Siokas now beneficially owns 4,164,789 common shares in Cosmos Health.Greg Si

1/21/25 3:00:00 PM ET

$COSM

Other Pharmaceuticals

Health Care

Cosmos Health Issues Letter to Shareholders

CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders.Dear Cosmos Health Shareholders,It has been just over a year since my previous shareholder letter, and I would like to express my sincere gratitude for your continued support. We have achieved many positive milestone

11/12/24 12:01:41 PM ET

$COSM

Other Pharmaceuticals

Health Care

SEC Form 10-K filed by Cosmos Health Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$COSM

SEC Form 10-K filed by Cosmos Health Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$COSM

$COSM
Insider Purchases

Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

$COSM
Insider Trading

Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

$COSM
Press Releases

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to Book Value

Cosmos Health Continues UK Retail Expansion for C-Scrub; Now Available at Superdrug, the UK's Second-Largest Beauty and Health Retailer

$COSM
SEC Filings

Amendment: SEC Form S-3/A filed by Cosmos Health Inc.

SEC Form 424B3 filed by Cosmos Health Inc.

Cosmos Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

$COSM
Leadership Updates

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

$COSM
Financials

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

Cosmos Health Issues Letter to Shareholders

$COSM
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

SEC Form SC 13G filed by Cosmos Health Inc.

SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

SEC Form 10-K filed by Cosmos Health Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $COSM

SEC Form 10-K filed by Cosmos Health Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $COSM

$COSM Insider Purchases

Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

$COSM Insider Trading

Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

$COSM Press Releases

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to Book Value

Cosmos Health Continues UK Retail Expansion for C-Scrub; Now Available at Superdrug, the UK's Second-Largest Beauty and Health Retailer

$COSM SEC Filings

Amendment: SEC Form S-3/A filed by Cosmos Health Inc.

SEC Form 424B3 filed by Cosmos Health Inc.

Cosmos Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

$COSM Leadership Updates

Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

$COSM Financials

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

Cosmos Health Issues Letter to Shareholders

$COSM Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

SEC Form SC 13G filed by Cosmos Health Inc.

SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

Recent Analyst Ratings for
$COSM

Recent Analyst Ratings for
$COSM

$COSM
Insider Purchases

$COSM
Insider Trading

$COSM
Press Releases

$COSM
SEC Filings

$COSM
Leadership Updates

$COSM
Financials

$COSM
Large Ownership Changes